Aribio Lab Sees Dramatic Limit-Up Reversal... Attention on AR1001 Phase 3 Trial Results and Upcoming FDA Discussions
Aribio Lab's stock price is staging a dramatic reversal. After hitting the limit-down the previous day and falling more than 20% during intraday trading on the 18th, the stock surged all the way to the limit-up. Market attention is focused on the results of the global Phase 3 trial of AR1001, an ora

Aribio Lab's stock price is staging a dramatic reversal. After hitting the limit-down the previous day and falling more than 20% during intraday trading on the 18th, the stock surged all the way to the limit-up. Market attention is focused on the results of the global Phase 3 trial of AR1001, an oral Alzheimer's disease treatment, and the company's plans for future discussions with the U.S. Food and Drug Administration (FDA).
On the morning of the 18th, Aribio Lab recorded the limit-up, trading at 5,290 won, up 1,220 won (29.98%) from the previous trading day.
■ Key Results of AR1001 Global Phase 3 Trial (POLARIS-AD)
On the 16th (U.S. Eastern Time), AriBio announced the key results of POLARIS-AD, the global Phase 3 clinical trial of AR1001, through the global press release distribution service GlobeNewswire.
According to AriBio, in an analysis of 604 patients in the pre-specified monotherapy group, AR1001 met its primary efficacy endpoint.
• At week 52, the Clinical Dementia Rating Sum of Boxes (CDR-SB) showed worsening that was 0.44 points less than the placebo group, slowing the rate of clinical decline by 31%. The p-value indicating statistical significance was 0.0266. • In the evaluation of the entire patient group of 1,535 patients, a treatment difference of -0.11 points was observed compared to placebo, but statistical significance was not achieved (p-value 0.4015). • However, this clinical trial set its primary efficacy objective as achieving a statistically significant treatment difference in at least one of the two groups — the overall patient group and the monotherapy patient group — according to the pre-specified statistical analysis procedure.
In the secondary cognitive function assessment, the Mini-Mental State Examination (MMSE) results for the monotherapy patient group showed a difference of 0.7 points compared to placebo, with a p-value of 0.0232, indicating nominal statistical significance.
In the cerebrospinal fluid biomarker analysis, cyclic guanosine monophosphate (cGMP) levels increased compared to placebo in both the overall patient group and the monotherapy patient group. The company explained that these results support the target engagement of AR1001 in the central nervous system.
■ Safety Assessment
The incidence of serious adverse events was 10.0% in the AR1001 treatment group and 9.8% in the placebo group. The rates of drug discontinuation due to adverse events were 5.2% and 1.7%, respectively.
■ Lead Investigator's Assessment
Dr. Sharon Sha, professor at Stanford University in the U.S. and lead investigator of the global clinical trial, gave a positive assessment of the clinical outcomes and safety in the monotherapy patient group. However, she also noted the need for further evaluation of the results in the overall patient group, secondary endpoints, and biomarkers. ■ FDA Discussion Plans and Key Points to Watch
AriBio stated that it plans to present additional analysis results at academic conferences and to discuss the full clinical trial results with the FDA in order to determine the future development direction of AR1001.
After hitting the limit-down the previous day, Aribio Lab's stock reached the limit-up on this day after falling more than 20% intraday, showing extreme stock price volatility. The content of future discussions with the FDA and whether additional clinical data will be disclosed are emerging as key points of interest.
However, the plan for discussions with the FDA does not imply the completion of a new drug application or product approval, and the direct background of the limit-up has not yet been confirmed.
[Some AI assistance was used in producing this article. This article does not recommend buying or selling any specific stock, and investment decisions and responsibilities lie with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



